ABSTRACT
Purpose Pregnancy is a valuable model to study the association between DNA methylation and several cardiometabolic traits, due to its direct potential to influence mother’s and child’s health. Epigenetics in Pregnancy (EPIPREG) is a population-based sample with the aim to study associations between DNA-methylation in pregnancy and cardiometabolic traits in South Asian and European pregnant women and their offspring.
Participants In EPIPREG we have quantified epigenome-wide DNA methylation in maternal peripheral blood leukocytes in gestational week 28±1 in Europeans (n=312) and South Asians (n=168) that participated in the population-based cohort STORK Groruddalen, in Norway. DNA methylation was measured with Infinium MethylationEPIC Kit (850k sites), with technical validation of four CpG sites using bisulphite pyrosequencing in a subset (n=30). The sample is well characterized with few missing data on e.g. genotype, universal screening for gestational diabetes, objectively measured physical activity, bioelectrical impedance, anthropometrics, biochemical measurements, and a biobank with maternal serum and plasma, urine, placenta tissue. In offspring, we have repeated ultrasounds during pregnancy, cord blood, and anthropometrics up to 4 years of age.
Results to date We have quantified DNA methylation in peripheral blood leukocytes in nearly all eligible women from the STORK Groruddalen study, to minimize the risk of selection bias. Genetic principal components distinctly separated Europeans and South Asian women, which fully corresponded with the self-reported ethnicity. Technical validation of 4 CpG sites from the methylation bead chip showed high concordance with bisulfite pyrosequencing (R=0.98, p<0.001).
Future plans We plan to study associations between DNA methylation and cardiometabolic traits and outcomes. We hope to identify cohorts with similar data to replicate our findings, collaborate on joint efforts such as meta-analysis, and serve as a replication cohort for other studies.
Strengths and limitations of this study
- Epigenome-wide DNA methylation data in maternal peripheral blood leukocytes in gestational week 28±1 in 312 Europeans and 168 South Asians living in Norway
- EPIPREG’s population-based design and comprehensive phenotyping allows for studies of a wide range of phenotypic traits, exposures and outcomes in relation to DNA methylation
- The inclusion of women with both European and South Asian ethnic background enables interesting studies into the role of DNA methylation in ethnic disparities in health.
- The wide range of collected phenotypes, exposures and outcomes makes the EPIPREG sample well suited to serve as a replication cohort for other cohorts with DNA methylation data
- The EPIPREG sample has limited statistical power for epigenome-wide association studies, and we are interested in collaborative efforts such as meta-analysis of several cohorts
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
EPIPREG is supported by the South Eastern Norway Regional Health Authority, and the Norwegian Diabetes Association. G.H.M. is supported by the Norwegian Research Council (Post doctoral mobility research grant 287198), and have received funding support by Nils Normans minnegave.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The STORK G study including the collection of data on genetics and epigenetics is approved by the Norwegian Regional Committee for Medical Health Research Ethics South East (ref.number 2015/1035). We obtained written informed consent from all participants before any study-related procedure.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data analysed are available from the corresponding author on reasonable request
